Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis

Bone Marrow Transplantation (2024)Cite this article

Subjects

Multiple myeloma (MM) is a clonal neoplastic proliferation of plasma cells that accounts for 1% of all cancers and 10–15% of hematological malignancies.

Cytogenetic aberrations, detected by fluorescent in situ hybridization (FISH), directly impact prognosis and stratify patients into standard-risk and high-risk cytogenetics groups. 85% of newly diagnosed MM patients (NDMM) have standard-risk cytogenetics according to Revised International Staging System (R-ISS).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–96.

    Article  PubMed  Google Scholar 

  2. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, et al. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022;12:47.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol J Am Soc Clin Oncol. 2007;25:2434–41.

    Article  Google Scholar 

  4. Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguiñano JM, et al. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). Leuk Lymphoma. 2022;63:3438–47.

    Article  PubMed  CAS  Google Scholar 

  5. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol J Am Soc Clin Oncol. 2019;37:589–97.

    Article  CAS  Google Scholar 

  6. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.

    Article  PubMed  CAS  Google Scholar 

  7. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2019;394:29–38.

    Article  CAS  Google Scholar 

  9. Byun JM, Park SS, Yoon SS, Ahn A, Kim M, Lee JY, et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Res. 2023;58:83–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 -. Identifier NCT04934475, Minimal Residual Disease Adapted Strategy (MIDAS); 2021; [about 4 screens]. Available from: https://clinicaltrials.gov/study/NCT04934475.

Download references

Acknowledgements

We would like to express our sincere gratitude to the patients and their families. We also extend our appreciation to our colleagues for their dedication in managing patient care and supporting the study.

Author information

Author notes

  1. These authors contributed equally: Andrea Poveda-García, Estela Ruiz.

Authors and Affiliations

  1. Department of Hematology, Virgen de la Arrixaca University Hospital, Murcia, Spain

    Andrea Poveda-García, Estela Ruiz, María José Moreno, Ignacio Español, Andrés Sánchez-Salinas, Ana María García-Hernández, Miguel Blanquer, Inmaculada Martínez, María Sánchez-Villalobos, María Carmen García Garay, Eduardo Salido, Ángela Heredia, Begoña Navarro-Almenzar, Jorge Monserrat, José Antonio Sánchez-Salas, Antonio José Martínez-Mellado, José M. Moraleda, Vanessa Roldán & Valentín Cabañas

  2. Stem Cell Transplant and Advanced Therapies Unit. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain

    María José Moreno, Ignacio Español, Andrés Sánchez-Salinas, Ana María García-Hernández, Miguel Blanquer, Inmaculada Martínez, María Sánchez-Villalobos, Eduardo Salido, Antonio José Martínez-Mellado, José M. Moraleda, Vanessa Roldán & Valentín Cabañas

  3. Department of Immunology, Virgen de la Arrixaca University Hospital, Murcia, Spain

    Alfredo Minguela, José Antonio Campillo, Ruth López-Hernández & José Antonio Galián

  4. Immunology and immunotolerance in transplants and immune-based diseases. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain

    Alfredo Minguela, José Antonio Campillo, Ruth López-Hernández & José Antonio Galián

Authors
  1. Andrea Poveda-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Estela Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María José Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ignacio Español
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrés Sánchez-Salinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ana María García-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miguel Blanquer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Inmaculada Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. María Sánchez-Villalobos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. María Carmen García Garay
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eduardo Salido
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ángela Heredia
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Begoña Navarro-Almenzar
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jorge Monserrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. José Antonio Sánchez-Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Antonio José Martínez-Mellado
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Alfredo Minguela
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. José Antonio Campillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Ruth López-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. José Antonio Galián
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. José M. Moraleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Vanessa Roldán
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Valentín Cabañas
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

APG, ERR and VC participated in conception and design of the work and participated in the writing of the manuscript draft. APG, ERR, VC, IEM, AHC, AJSS and AJMM contributed to data collection. APG, ERR and VC performed data analysis and interpretation. MBB, AMGH and IMM were responsible for the collection and infusion of hematopoietic progenitors. VC, MJMB, IEM, JMC, BNA and ASS have conducted patient monitoring. ESF, MCGG and MSV performed the bone marrow biopsy to diagnose and evaluate the response. AMP evaluated MRD by flow cytometry. All authors revised the article and gave approval of the final version to be published.

Corresponding author

Correspondence to Valentín Cabañas.

Ethics declarations

Competing interests

V.C received honoraria for lectures, consulting and advisory boards from Johnson&Johnson®, BMS®, Sanofi®, Amgen®, Glaxo®, Pfizer®, BioGene®, Menarini®. I received travel grants from Johnson&Johnson®, BMS®, Amgen®, BioGene® and served on a Speakers’ Bureau for BMS®. Financing of Scientific Research: Janssen®. MJM received honoraria for lectures from Johnson&Johnson®.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poveda-García, A., Ruiz, E., Moreno, M.J. et al. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02404-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-024-02404-1

Search

Advanced search

Quick links